Identification and Management of Bipolar Depression
neuroscienceCME Multimedia SnackPremiere Date: Wednesday, December 4, 2013
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, December 4, 2016
Note: Credit Is No Longer Available
|Charles B. Nemeroff, MD, PhD
Professor of Psychiatry
Director, Institute for Early Life Adversity Research
University of Texas Dell Medical School
Professor and Chair Emeritus
Department of Psychiatry & Behavioral Sciences
University of Miami Miller School of Medicine
|Robert M.A. Hirschfeld, MD
Titus H. Harris Chair
Harry K. Davis Professor
Professor and Chairperson
Department of Psychiatry
University of Texas Medical Branch
Bipolar disorder (BPD) is a mood disorder characterized by alternating periods of depression and mania/hypomania or mixed states. Patients with BPD spend the majority of time in depressed states, so bipolar depression is, far and away, the more common presentation of bipolar disorders that psychiatrists, primary care physicians, and other clinicians see. Yet, bipolar depression is frequently misdiagnosed as major depression. Careful screening, assisted by evidence-based assessment tools such as the Mood Disorder Questionnaire, can improve diagnostic clarity and facilitate earlier, appropriate, pharmacological and psychotherapeutic management.(1)
It is critical for clinicians to be able to offer patients with bipolar depression the best possible care and ongoing management. Physicians in practice need to be able to interpret data on emerging agents for bipolar depression, evaluate these agents’ side effect profiles, and consider how new agents may change the way they treat patients.(2)
This CME Snack™ activity will inspire clinicians to carefully review their patients’ diagnoses of depression and screen for bipolar disorder. It will also highlight the best treatment options for patients with bipolar depression.
- Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161-174. PMID: 12633125.
- El-Mallakh RS, Elmaadawi AZ, Gao Y, et al. Current and emerging therapies for the management of bipolar disorders. J Cent Nerv Syst Dis. 2011;3:189-197. PMID: 23861648.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is:
Clinicians will routinely screen all patients who present with depression for the possibility of bipolar depression/disorder.
At the end of this CE activity, participants should be able to:
- Use validated rating scales and questionnaires, in concert with measurement-based care principles, to objectively measure symptoms and response in bipolar depression, identifying patients with bipolar depression as opposed to unipolar depression or major depressive disorder.
- Evaluate newly available data regarding the safety and efficacy of the emerging treatment of bipolar depression.
This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.
Physicians, pharmacists, and other health care professionals with an interest in mood disorders.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-14-016-H01-P (recorded programs)
Activity Type: knowledge-based
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff has disclosed that he receives grants/research support from the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH). He serves as a consultant to Allergan, Inc.; Eli Lilly and Company; Shire Pharmaceuticals, Inc.; SK Pharma; Roche; Takeda Pharmaceuticals North America, Inc.; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; Skyland Trail; and AstraZeneca Pharmaceuticals (2009). He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Gratitude America; Cook Pharma, Inc. (2010); NovaDel Pharma, Inc; and Skyland Trail. He is a stockholder of CeNeRx BioPharma; NovaDel Pharma, Inc., PharmaNeuroBoost; Reevax Pharmaceuticals LLC; and Xhale, Inc. His other financial Interests include CeNeRx BioPharma and PharmaNeuroBoost. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Hirschfeld has received royalties from Jones and Bartlett Publishers. He serves as a consultant to BioStrategies Group; Grey healthcare Group, Inc.; and Merck Manual Editorial Board. He has received honoraria from BioStrategies Group; CMEology; Health and Wellness Partners; Physicians Postgraduate Press, Inc.
Tony Graham, MD (peer review) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Sunovion Pharmaceuticals, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).